Current treatment strategy of acute promyelocytic leukemia

被引：24
作者：
Mi J. [1 ]
机构：
[1] Department of Hematology, Shanghai Institute of Hematology, Rui-Jin Hospital, Shanghai JiaoTong University School of Medicine
来源：
Frontiers of Medicine | 2011年 / 5卷 / 4期
关键词：
acute promyelocytic leukemia; all-trans retinoic acid; arsenic trioxide;
D O I：
10.1007/s11684-011-0169-z
中图分类号：
学科分类号：
摘要：
Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML). The prognosis of APL has changed from the worst among the AMLs to currently the best. The application of all-trans retinoic acid (ATRA) in the induction therapy of APL decreases the high mortality of newly diagnosed patients, thereby significantly improving the response rate. ATRA combined with anthracycline-based chemotherapy is the current standard treatment, and for high-risk patients, high doses cytarabine have a beneficial effect on relapse prevention. In recent years, the indications of arsenic trioxide (ATO) therapy for APL have been extended from the salvage therapy for relapse patients to the first-line treatment of de novo APL. The introduction of both ATRA and ATO represents great achievements in translational medicine. In this review article, we discuss the therapeutic strategies for this disease, including the initial approaches to newly diagnosed patients, prevention, and treatment of side effects and relapse to ensure the best and timely treatment for each newly diagnosed APL patient. © 2011 Higher Education Press and Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：341 / 347
页数：6
相关论文
共 58 条
[1]  
Chen S.J., Zelent A., Tong J.H., Yu H.Q., Wang Z.Y., Derre J., Berger R., Waxman S., Chen Z., Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11
[2]  
17)(q23
[3]  
q21) in a patient with acute promyelocytic leukemia, J Clin Invest, 91, 5, pp. 2260-2267, (1993)
[4]  
Wells R.A., Catzavelos C., Kamel-Reid S., Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia, Nat Genet, 17, 1, pp. 109-113, (1997)
[5]  
Redner R.L., Rush E.A., Faas S., Rudert W.A., Corey S.J., The t(5
[6]  
17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion, Blood, 87, 3, pp. 882-886, (1996)
[7]  
Arnould C., Philippe C., Bourdon V., Grgoire M.J., Berger R., Jonveaux P., The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia, Hum Mol Genet, 8, 9, pp. 1741-1749, (1999)
[8]  
Catalano A., Dawson M.A., Somana K., Opat S., Schwarer A., Campbell L.J., Iland H., The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia, Blood, 110, 12, pp. 4073-4076, (2007)
[9]  
Kondo T., Mori A., Darmanin S., Hashino S., Tanaka J., Asaka M., The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4
[10]  
17)-positive acute promyelocytic leukemia, Haematologica, 93, 9, pp. 1414-1416, (2008)
123456